Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00020709 · ClinicalTrials.gov registry record · Phase 3
Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery
A Phase 3 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 3
- Development phase
- 840
- Enrollment target
NCT00020709: Completed Phase 3 study, sponsored by National Cancer Institute (NCI).
NCT00020709 is a Phase 3 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 840 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00020709, a Phase 3 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 840 participants
- Enrollment target
Study Summary
Randomized phase III trial to compare the effectiveness of combination chemotherapy plus radiation therapy with or without gefitinib in treating unresectable stage III non-small cell lung cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Biological therapies such as gefitinib may interfere with the growth of the tumor cells and slow the growth of tumors. It is not yet known whether combination chemotherapy plus radiation therapy is more effective with or without gefitinib in treating non-small cell lung cancer
Interventions
- DRUG cisplatin
- DRUG docetaxel
- DRUG etoposide
- RADIATION radiation therapy
- DRUG gefitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 840 participants |
| Start Date | 2001-06 |
| Phase | Phase 3 |
What the finished NCT00020709 record still lists
NCT00020709 is an interventional study that assigns participants to a tested intervention. The registered 840 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 5 interventions - of which cisplatin is the first listed.
NCT00020709 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00020709 about?
NCT00020709 is a clinical study titled "Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery". Randomized phase III trial to compare the effectiveness of combination chemotherapy plus radiation therapy with or without gefitinib in treating unresectable stage III non-small cell lung cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or ...
What is the current status of trial NCT00020709?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 840 participants. The study started on 2001-06.
What interventions are being tested in trial NCT00020709?
The interventions under investigation include: cisplatin (DRUG), docetaxel (DRUG), etoposide (DRUG), radiation therapy (RADIATION), gefitinib (DRUG).
Who is sponsoring clinical trial NCT00020709?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00020709's enrollment target sits among peer trials
840 392nd of 2000 higher than 1,607 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04831580 · 840 participants · NA
A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer
- NCT04976881 · 840 participants · NA
Promoting Preconception Care and Diabetes Self-Management Among Reproductive-Aged Women With Diabetes
- NCT04985903 · 840 participants · NA
Baby Steps III: Testing a Clinician and Patient Intervention to Promote Smoking Cessation Among Pregnant Women
- NCT05384626 · 840 participants · Phase 1
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia